AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26265125
Drug: Mannitol treatment
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol treatment in patients with larger baseline hematomas (≥15 mL)
Trial: 26265125
Drug: Mannitol treatment
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol treatment
Trial: 23765639
Drug: Vardenafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10 mg/day, for 12 weeks)
Trial: 2894399
Drug: DTP-AC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP-AC vaccine
Trial: 2894399
Drug: DTP-WC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP-WC vaccine
Trial: 29102669
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of filtered air containing particulate mixture (PM 10, PM 2.5, PM 1.0 and PM 0.5 µm)
Trial: 29102669
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of filtered air mixture (control)
Trial: 27377521
Drug: Single-Dose (SID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose (SID) bowel preparation
Trial: 27377521
Drug: Split-Dose (SPD1)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-Dose (SPD1) bowel preparation
Trial: 27377521
Drug: Split-Dose (SPD2)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-Dose (SPD2) bowel preparation
Trial: 24526078
Drug: Non-operative caries
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative caries treatment and prevention (NOCTP) programme
Trial: 23363790
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with dendritic cell and cytokine-induced killer cell (DC-CIK) immunotherapy
Trial: 17964871
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy + granulocyte-colony stimulating factor (5 microg/kg/day for 6 days)
Trial: 17964871
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy + granulocyte-colony stimulating factor (15 microg/kg/day s.c. for 6 days)
Trial: 17964871
Drug: granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: granulocyte-colony stimulating factor treatment
Trial: 15642561
Drug: atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin + amlodipine
Trial: 15642561
Drug: atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin + placebo
Trial: 11509086
Drug: Vinpocetine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine in combination with low‐molecular weight dextran (n = 15)
Trial: 9446908
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of all individuals in a class together with family members of positive cases
Trial: 9446908
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of only egg positive cases
Trial: 7916157
Drug: High-dose neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose neuroleptic treatment (above 375 mg equivalent of chlorpromazine)
Trial: 7916157
Drug: Low-dose neuroleptic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose neuroleptic treatment (375 mg equivalent of chlorpromazine or below)
Trial: 3282336
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg taken orally three times daily for six months
Trial: 3282336
Drug: Placebo taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally three times daily for six months
Trial: 24853643
Drug: Cholecalciferol 50,000
RxNorm normalized name: CHOLECALCIFEROL 50,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 50,000 IU with 0 g fat (Group 1)
Trial: 24853643
Drug: Cholecalciferol 50,000
RxNorm normalized name: CHOLECALCIFEROL 50,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 50,000 IU with 15 g fat (Group 2)
Trial: 24853643
Drug: Cholecalciferol 50,000
RxNorm normalized name: CHOLECALCIFEROL 50,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 50,000 IU with 30 g fat (Group 3)
Trial: 23489780
Drug: Ultrasound-guided percutaneous
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided percutaneous drainage and alcohol sclerotherapy with single-session multiple injections
Trial: 19663091
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus rehabilitation training
Trial: 15238420
Drug: Interferon‐alpha (IFN‐alpha)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐alpha (IFN‐alpha) maintenance therapy
Trial: 11740135
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 25-50 mg once daily
Trial: 22985218
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise (1 hour per session, twice a week for 12 weeks)
Trial: 20451040
Drug: Methylprednisolone (32-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (32-8 mg once daily for 20 days)
Trial: 28501884
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 20 days)
Trial: 19126019
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of 2025 U Botulinum toxin type A (BTA)
Trial: 16787142
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using LHRH agonist or orchiectomy plus dexamethasone and somatostatin analogue
Trial: 10385667
Drug: 9 million
RxNorm normalized name: INTERFERON ALFA-2A,RECOMBINANT 9 MILLION UNT/SYR INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 million units (MU) of IFN‐alpha‐2a, Roferon‐A, thrice weekly for 6 months
Trial: 2531606
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine
Trial: 6495087
Drug: Intramuscular atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular atropine
Trial: 6401946
Drug: Intermittent intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intraoperative antibiotic irrigation
Trial: 28315149
Drug: Myofunctional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofunctional therapy (MT)
Trial: 31103811
Drug: Flap fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap fixation using adhesive tissue glue (FF-G)
Trial: 29508899
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (1.8 mg/m2 per cycle for ≤6 cycles)
Trial: 29508899
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC: fludarabine/cytarabine [ara‐C]/granulocyte colony‐stimulating factor, or ara‐C plus mitoxantrone, or high‐dose ara‐C for ≤4 cycles)
Trial: 17898949
Drug: Tongluo yangyin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongluo yangyin recipe (TLYYR) 200 mL in water decoction daily for 28 days
Trial: 17898949
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 100 mg and Vitamin B12 250 microg administered daily via intramuscular injection for 28 days
Trial: 15172082
Drug: Patch E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch E2 (delivering 50 microg per day, two patches per week)
Trial: 7863255
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg at night
Trial: 2815851
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg digoxin tablets
Trial: 2815851
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg digoxin capsules
Trial: 2815851
Drug: Cumulative urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative urinary excretion of digoxin
Trial: 1097099
Drug: Adriamycin (40-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (40-75 mg/m intravenously every 3 weeks)
Trial: 31834217
Drug: Robotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic treatment using a set of 4 devices
Trial: 25678773
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant bovine basic fibroblast growth factor (rb‐bFGF) and 0.5% levofloxacin
Trial: 22998746
Drug: Patching daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching daily 6 days weekly for 8 hr or more
Trial: 22998746
Drug: Patching daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching daily 6 days weekly
Trial: 12766664
Drug: Nonsteroidal antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal antiinflammatory drugs (NSAIDs) after tonsillectomy
Trial: 1573126
Drug: 5-HT2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT2 receptor antagonist, ritanserin
Trial: 4014253
Drug: Pediatric extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric extension set for drug delivery
Trial: 31662003
Drug: Regional arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional arterial infusion (RAI) combined with early enteral nutrition (EEN)
Trial: 25069650
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human thrombopoietin (rhTPO), administered subcutaneously at a daily dose of 15,000 U from the first day after transplantation.
Trial: 25069650
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rhTPO treatment).
Trial: 25069650
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human thrombopoietin (rhTPO) and control group (no rhTPO treatment).
Trial: 23212147
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once daily (M group)
Trial: 23212147
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg once daily (S group)
Trial: 23212147
Drug: Antimuscarinic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic therapy (Control group)
Trial: 12784978
Drug: Quixil fibrin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quixil fibrin glue (0.5 mL to each tonsillar fossa and 0.5 mL to the nasopharynx in adenoidectomy)
Trial: 11014398
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) distraction during physical therapy
Trial: 11014398
Drug: No distraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No distraction during physical therapy
Trial: 8345812
Drug: High cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High cholesterol diet (800 mg/d)
Trial: 8345812
Drug: Low cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low cholesterol diet (250 mg/d)
Trial: 2953318
Drug: Hydration plus
RxNorm normalized name: Biotrue Hydration Plus Multi-Purpose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration plus intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2)
Trial: 2953318
Drug: Hydration plus
RxNorm normalized name: Biotrue Hydration Plus Multi-Purpose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration plus intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3)
Trial: 29436756
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg every 2 weeks (increased to 150 mg every 2 weeks at week 12 if necessary)
Trial: 19463374
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg daily maintenance dose
Trial: 19463374
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg daily maintenance dose
Trial: 12924542
Drug: SQV 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV 1400 mg without itraconazole
Trial: 12924542
Drug: SQV 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV 1200 mg with itraconazole
Trial: 12924542
Drug: SQV 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV 800 mg with itraconazole
Trial: 11039131
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sodium cromoglycate (SCG) 20 min before exercise
Trial: 11039131
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sodium cromoglycate (SCG) 20 min before exercise
Trial: 11039131
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sodium cromoglycate (SCG) 120 min before exercise
Trial: 11039131
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sodium cromoglycate (SCG) 120 min before exercise
Trial: 11039131
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SCG 20 min before exercise
Trial: 11039131
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg SCG 120 min before exercise
Trial: 11039131
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg SCG 20 min before exercise
Trial: 11039131
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg SCG 120 min before exercise
Trial: 8479193
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) in combination with external beam (n = 27)
Trial: 29751787
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a SC 44 μg 3×/week
Trial: 29751787
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a SC 22 μg 3×/week
Trial: 29751787
Drug: Placebo/delayed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/delayed treatment (DTx)
Trial: 18702958
Drug: Miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50 mg)
Trial: 12069449
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance ≤ 40 ml x min(‐1)
Trial: 12069449
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance from 41 to 55 ml x min(‐1)
Trial: 12069449
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance from 71 to 85 ml x min(‐1)
Trial: 29873212
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention combined with diazepam (2.5 mg once, twice a day)
Trial: 29873212
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment of sudden hearing loss (Control group)
Trial: 23113597
Drug: Resonance frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resonance frequency analysis (RFA) measurements at 8 weeks post-implant placement
Trial: 23113597
Drug: Resonance frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resonance frequency analysis (RFA) measurements at implant placement
Trial: 22240263
Drug: Colestimide 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide 3 g/day
Trial: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after first dose
Trial: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after second dose
Trial: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after third dose
Trial: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after last dose
Trial: 15803071
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and spinal stabilization exercises (30 minutes, 8 treatments over 8 weeks)
Trial: 15803071
Drug: 10 station
RxNorm normalized name: Brevibacterium stationis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 station exercise class (aerobic exercises, spinal stabilization exercises, and manual therapy, 8 treatments over 8 weeks)
Trial: 12480510
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment with standard needles at acupoint LI11 for 30 min
Trial: 12480510
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with placebo needles at acupoint LI11 for 30 min
Trial: 2289222
Drug: beta‐cyclodextrin‐piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐cyclodextrin‐piroxicam (20 mg daily for eight weeks)
Trial: 2289222
Drug: tenoxicam (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tenoxicam (dosage not specified, for eight weeks)
Trial: 7002483
Drug: Rociverine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rociverine (10 or 20 mg given intravenously)
Trial: 7002483
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (20 or 40 mg given intravenously)
Trial: 23429925
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral glucosamine sulphate)
Trial: 17522506
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b 10 MIU/m (IFN-I group) thrice weekly for 16 weeks
Trial: 16838645
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon therapy
Trial: 15221054
Drug: UDC +
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDC + CDC (125 mg urso-/chenodeoxycholic acid per 25 kg body weight)
Trial: 15221054
Drug: M +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M + UDC + CDC (62.5 mg UDC/CDC plus 125 mg menthol per 25 kg body weight)
Trial: 12063630
Drug: Fusafungine in
RxNorm normalized name: fusafungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusafungine in spray 4 times daily
Trial: 12063630
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard postoperative therapy)
Trial: 12063630
Drug: Fusafungine in
RxNorm normalized name: fusafungin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusafungine in spray
Trial: 7855226
Drug: Pindolol, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol, 30 mg orally
Trial: 7855226
Drug: L-5-HTP, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-HTP, 200 mg PO
Trial: 998549
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of pyridoxine supplementation
Trial: 998549
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of pyridoxine supplementation